Live Breaking News & Updates on Suppresses Psychostimulant Behavior

Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneously address positive, negative and cognitive symptoms of schizophreniaSosei Heptares will receive EUR 25 million upfront from Boehringer Ingelheim and is eligible for an option exercise payment of EUR 60 million and further milestone payments totaling up to EUR 670 million plus tiered royalties Ingelheim, Germany, Tokyo, Japan and Cambridge, UK, ....

United Kingdom , City Of , Soult Ukpyolsi , South Korea , New York , United States , Rheinland Pfalz , Sosei Heptares , Erica Hollingsworth , Kentaro Tahara , Frazer Hall , Sosei Heptare , Linda Ruckel , Reinhard Malin , Shinichiro Nishishita , Maya Bennison , Matt Barnes , Hugh Marston , Group Of Schizophrenias , Schizophrenia Research , Discovery Research At Boehringer Ingelheim , Sosei Group , Medistrava Consulting For International Media , Sosei Group Corporation Heptares , Sosei Group Corporation , Boehringer Ingelheim ,